

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER
AND SIX MONTHS ENDED 30, SEPTEMBER 2016.

(Rs. In Lacs)

Sr. No.	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for the previous year ended	Previous year ended
		30/09/16	30/06/16	30/09/15	30/09/16	30/09/15	31/03/2016
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	Audited (9 M)
1	Income from Operations						
	Net Sales/Income from Operations & Other Operating Income (net of Excise Duty)	4,477.79	3,783.26	11,299.48	8,261.05	25,495.30	25,345.48
	Total Income from Operations (net)	4,477.79	3,783.26	11,299.48	8,261.05	25,495.30	25,345.48
2	Expenses						
	(a) Cost of Material Consumed	2,113.91	2,190.43	9,550.67	4,304.34	22,880.34	20,726.18
	(b) Purchase of Stock-in-trade	-	-	355.66	-	865.87	355.66
	(c) Change in Inventories of Finished Goods, Work-in-progress and Stock in trade	2,178.16	13,925.35	(553.31)	16,103.51	(2,357.16)	12,143.34
	(d) Employee benefit Expense	576.47*	555.31	549.10	1,131.77	911.81	1,654.61
	(e) Depreciation & Ammortisation Expense	503.45	502.64	499.57	1,006.09	1,053.27	1,501.46
	(f) Other Expenses	915.62	939.47	964.73	1,855.09	2,092.05	3,849.63
	Total Expenses	6,287.61	18,113.20	11,366.42	24,400.81	25,446.18	40,230.87
3	Profit from Operations before Other Income, Finance Cost & Exceptional Items (1-2)	(1,809.82)	(14,329.93)	(66.94)	(16,139.75)	49.12	(14,885.39)
4	Other Income	84.41	48.64	71.50	133.05	190.76	194.93
5	Profit from Ordinary activities before Finance Cost & Exceptional Items (3+4)	(1,725.41)	(14,281.29)	4.56	(16,006.70)	239.88	(14,690.46)
6	Finance Cost	138.19	1,358.00	1,672.05	1,496.20	6,647.40	7,098.15
7	Profit from Ordinary activities after Finance Cost & Exceptional Items (5-6)	(1,863.60)	(15,639.30)	(1,667.49)	(17,502.90)	(6,407.52)	(21,788.61)
8	Exceptional Items	10,184.15	2,298.92	5,911.38	12,483.07	9,736.62	7,135.21
9	Profit from Ordinary activities before Tax (7-8)	(12,047.76)	(17,938.22)	(7,578.87)	(29,985.97)	(16,144.14)	(28,923.82)
10	Tax Expense	-	-	-	-	(466.36)	996.57
11	Net Profit (+) / Loss (-) from Ordinary Activities after tax (9-10)	(12,047.76)	(17,938.22)	(7,578.87)	(29,985.97)	(15,677.78)	(29,920.39)
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	Net Profit (+) / Loss (-) for the period (11 -12)	(12,047.76)	(17,938.22)	(7,578.87)	(29,985.97)	(15,677.78)	(29,920.39)
14	Paid up Equity Share Capital (Face value of Rs. 2/- each)	2,378.71	2,378.71	2,378.71	2,378.71	2,378.71	2,378.71
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	(21,899.66)
16	Earnings Per Share (of Rs.2/- each) (not annualised)						
	a) Basic (in Rs.)	(10.13)	(15.08)	(6.37)	(25.21)	(13.18)	(25.16)
	b) Diluted (in Rs.)	(9.90)	(14.74)	(6.23)	(24.64)	(12.88)	(24.59)

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.

Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities

		STANDALONE	
Particulars		As at 30.09.2016	As at 31.03.2016
A.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a.) Share Capital	2,378.71	2,378.71
	(b.) Reserves and Surplus	(51,885.89)	(21,899.66)
	(c.) Money received against share warrants	-	-
	Sub-Total - ShareHolders Funds	(49,507.18)	(19,520.95)
2	Convertible Warrants	1,372.15	1,372.15
	Share Application Money	-	-
3	Minority Interest	-	-
4	Non Current Liabilities		
	(a.) Long term borrowings	54,383.49	54,359.93
	(b.) Deferred Tax Liabilities (Net)	2,150.66	2,150.66
	(c.) Other Long Term Liabilities	-	-
	(d.) Long Term Provisions	153.37	153.37
	Sub-Total - Non current liabilities	56,687.52	56,663.96
5	Current Liabilities		
	(a.) Short term borrowings	29,685.08	29,271.98
	(b.) Trade Payables	4,166.28	4,002.83
	(c.) Other Current Liabilities	601.31	494.25
	(d.) Short term provision	-	-
	Sub-Total - Current liabilities	34,452.66	33,769.06
	TOTAL- EQUITY AND LIABILITIES	43,005.15	72,284.22
B.	ASSETS		
1	Non Current Assets		
	(a.) Fixed Assets	30,958.64	31,855.75
	(b.) Goodwill on consolidation	-	-
	(c.) Non Current Investments	6.22	6.22
	(d.) Deferred Tax Assets (Net)	-	-
	(e.) Long term Loans and Advances	-	-
	(f.) Other non-current assets	784.82	912.84
	Sub-Total - Non Current Assets	31,749.68	32,774.82
2	Current Assets		
	(a.) Current Investments	-	-
	(b.) Inventories	1,895.50	17,999.00
	(c.) Trade Receivables	5,957.31	18,317.53
	(d.) Cash and Cash equivalents	877.88	1,015.63
	(e.) Short term Loans and Advances	2,524.79	2,177.25
	(f.) Other Current Assets	-	-
	Sub-Total - Current Assets	11,255.47	39,509.41
	TOTAL - ASSETS	43,005.15	72,284.22

- Notes:** 1) The above results for the period ended September 30, 2016 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on November 10, 2016.
- 2) The Statutory Auditors of the Company has carried out the Limited Review of the above standalone results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
- 3) The company has not provided for interest amounting to Rs. 2637.24 Lacs on Loans for the period ended 30 September 2016, in view of the same has not been charged by various banks.
- 4) Previous years figures have been re-grouped and re-arranged wherever considered necessary.

Place : Mumbai
 Date : 10.11.2016
 Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.
 Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001
 www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships



For Sharon Bio-Medicine Ltd

Sayita Gowda
 Sayita Gowda
 Managing Director.